Product Code: ETC8837266 | Publication Date: Sep 2024 | Updated Date: May 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Summon Dutta | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The contract development and manufacturing organization (CDMO) segment for cell and gene therapy in the Philippines is gaining momentum. Companies are seeking CDMOs to scale up production, navigate regulatory pathways, and reduce time-to-market, creating new opportunities for local providers.
Contract development and manufacturing organizations (CDMOs) are playing an important role in the Philippines cell and gene therapy landscape. The need for specialized manufacturing capabilities, cost efficiency, and flexibility is pushing pharmaceutical companies to collaborate with CDMOs, supporting market growth.
The CDMO (Contract Development and Manufacturing Organization) segment faces capacity limitations, high capital investment requirements, and difficulties in maintaining compliance with global regulatory standards. Furthermore, the local ecosystem has limited integration of upstream and downstream manufacturing services.
The contract development and manufacturing organization (CDMO) market for cell and gene therapies in the Philippines is expected to grow rapidly due to the increasing demand for outsourced manufacturing services. As biotechnology companies seek cost-effective and efficient production solutions for cell and gene therapies, there is a growing opportunity for CDMOs to offer specialized services. Investment in this market would focus on enhancing local manufacturing capabilities, ensuring high-quality standards, and meeting the rising demand from both domestic and international biotechnology firms.
The government has been fostering the growth of Contract Development and Manufacturing Organizations (CDMO) that support cell and gene therapy production. Policies aim to attract foreign investments in the Philippines while supporting the local CDMO sector through incentives like tax breaks and infrastructure development. The government ensures that CDMOs adhere to stringent international guidelines and helps facilitate collaborations between CDMOs, biotech firms, and healthcare providers to create a robust manufacturing ecosystem for cutting-edge therapies.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Philippines Cell And Gene Therapy CDMO Market Overview |
3.1 Philippines Country Macro Economic Indicators |
3.2 Philippines Cell And Gene Therapy CDMO Market Revenues & Volume, 2021 & 2031F |
3.3 Philippines Cell And Gene Therapy CDMO Market - Industry Life Cycle |
3.4 Philippines Cell And Gene Therapy CDMO Market - Porter's Five Forces |
3.5 Philippines Cell And Gene Therapy CDMO Market Revenues & Volume Share, By Phase, 2021 & 2031F |
3.6 Philippines Cell And Gene Therapy CDMO Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.7 Philippines Cell And Gene Therapy CDMO Market Revenues & Volume Share, By Indication, 2021 & 2031F |
4 Philippines Cell And Gene Therapy CDMO Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Philippines Cell And Gene Therapy CDMO Market Trends |
6 Philippines Cell And Gene Therapy CDMO Market, By Types |
6.1 Philippines Cell And Gene Therapy CDMO Market, By Phase |
6.1.1 Overview and Analysis |
6.1.2 Philippines Cell And Gene Therapy CDMO Market Revenues & Volume, By Phase, 2021- 2031F |
6.1.3 Philippines Cell And Gene Therapy CDMO Market Revenues & Volume, By Pre-clinical, 2021- 2031F |
6.1.4 Philippines Cell And Gene Therapy CDMO Market Revenues & Volume, By Clinical, 2021- 2031F |
6.2 Philippines Cell And Gene Therapy CDMO Market, By Product Type |
6.2.1 Overview and Analysis |
6.2.2 Philippines Cell And Gene Therapy CDMO Market Revenues & Volume, By Gene Therapy, 2021- 2031F |
6.2.3 Philippines Cell And Gene Therapy CDMO Market Revenues & Volume, By Gene-Modified Cell Therapy, 2021- 2031F |
6.2.4 Philippines Cell And Gene Therapy CDMO Market Revenues & Volume, By Cell Therapy, 2021- 2031F |
6.3 Philippines Cell And Gene Therapy CDMO Market, By Indication |
6.3.1 Overview and Analysis |
6.3.2 Philippines Cell And Gene Therapy CDMO Market Revenues & Volume, By Oncology, 2021- 2031F |
6.3.3 Philippines Cell And Gene Therapy CDMO Market Revenues & Volume, By Infectious Diseases, 2021- 2031F |
6.3.4 Philippines Cell And Gene Therapy CDMO Market Revenues & Volume, By Neurological disorders, 2021- 2031F |
6.3.5 Philippines Cell And Gene Therapy CDMO Market Revenues & Volume, By Rare Diseases, 2021- 2031F |
6.3.6 Philippines Cell And Gene Therapy CDMO Market Revenues & Volume, By Others, 2021- 2031F |
7 Philippines Cell And Gene Therapy CDMO Market Import-Export Trade Statistics |
7.1 Philippines Cell And Gene Therapy CDMO Market Export to Major Countries |
7.2 Philippines Cell And Gene Therapy CDMO Market Imports from Major Countries |
8 Philippines Cell And Gene Therapy CDMO Market Key Performance Indicators |
9 Philippines Cell And Gene Therapy CDMO Market - Opportunity Assessment |
9.1 Philippines Cell And Gene Therapy CDMO Market Opportunity Assessment, By Phase, 2021 & 2031F |
9.2 Philippines Cell And Gene Therapy CDMO Market Opportunity Assessment, By Product Type, 2021 & 2031F |
9.3 Philippines Cell And Gene Therapy CDMO Market Opportunity Assessment, By Indication, 2021 & 2031F |
10 Philippines Cell And Gene Therapy CDMO Market - Competitive Landscape |
10.1 Philippines Cell And Gene Therapy CDMO Market Revenue Share, By Companies, 2024 |
10.2 Philippines Cell And Gene Therapy CDMO Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |